Quick Summary:
In the rapidly evolving Bladder Cancer Therapeutics industry, insight, foresight and strategic decision-making is fundamental in securing a competitive edge. Our comprehensive Global Bladder Cancer Therapeutics Market Report provides robust forecasts up to 2030, paired with unrivalled insight on current market trends and opportunities. Delve into our expert analysis of the sector's projected growth, which is set to reach a revised size of US$345.3 Million by 2030.
In-depth country-based analyses reveal key thriving markets including the US, estimated at $66.6 million in 2022, and China, forecast to expand at 7.3% CAGR over the 2022-2030 period. Get to know your influential competitors, with featured profiles of 62 significant market players ranging from AstraZeneca plc to Pfizer, Inc. The report also provides exclusive content including a ranking on global competitiveness, market shares, and market presence across varied geographies.
Global Bladder Cancer Therapeutics Market to Reach $345.3 Million by 2030
The global market for Bladder Cancer Therapeutics estimated at US$244.4 Million in the year 2022, is projected to reach a revised size of US$345.3 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030. Transitional Cell Bladder Cancer, one of the segments analyzed in the report, is projected to record a 3.9% CAGR and reach US$114.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non Muscle Invasive / Superficial Bladder Cancer segment is readjusted to a revised 5.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $66.6 Million, While China is Forecast to Grow at 7.3% CAGR
The Bladder Cancer Therapeutics market in the U.S. is estimated at US$66.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$72.2 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 3.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$46.5 Million by the year 2030.Select Competitors (Total 62 Featured) -
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Novartis International AG
- Pfizer, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Bladder Cancer Therapeutics?
What is the growth rate of the Global Market for Bladder Cancer Therapeutics?
What is the forecasted size of the Global Market for Bladder Cancer Therapeutics?
Who are the key companies in the Global Market for Bladder Cancer Therapeutics?
| Report Attribute | Details |
|---|---|
| No. of Pages | 283 |
| Published | November 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 244.4 Million |
| Forecasted Market Value ( USD | $ 345.3 Million |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Novartis International AG
- Pfizer, Inc.
